# Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma

> **NCT01933711** · PHASE3 · UNKNOWN · sponsor: **University Hospital Heidelberg** · enrollment: 328 (estimated)

## Conditions studied

- CD20+ Aggressive Lymphoma, Mantle Cell Lymphoma

## Interventions

- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT01933711
- **Lead sponsor:** University Hospital Heidelberg
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2002-07
- **Primary completion:** 2016-12
- **Final completion:** 2018-12
- **Target enrollment:** 328 (ESTIMATED)
- **Last updated:** 2016-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01933711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01933711, "Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01933711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*